Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Board Changes

20 Oct 2021 07:00

RNS Number : 5782P
Roquefort Investments PLC
20 October 2021
 

20 October 2021

 

 

Roquefort Investments plc

("Roquefort Investments" or the "Company")

 

Board Changes

 

Roquefort Investments (LSE:ROQ), the investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, announces the appointment of Mr Mark Freeman as a non-executive director and the resignation of Mr Glenn Whiddon as non-executive director with effect from today.

 

Mr Freeman (aged 46) is a Chartered Accountant and has more than 25 years' experience in corporate finance and the public markets, with a focus on project development. Mr Freeman is a graduate of the University of Western Australia with a Bachelor of Commerce with a double major in Banking & Finance and Accounting as well as holding a Graduate Diploma in Applied Finance with a major in Investment Analysis from the Securities Institute of Australia. He has experience in strategic planning, business development, acquisitions and mergers, project commercialisation, project development and general management. Mr Freeman is currently a director of Pursuit Minerals Ltd (ASX:PUR), Calima Energy Ltd (ASX:CE1) and Grand Gulf Energy Ltd (ASX:GGE).

 

In addition, Mr Freeman is currently a director of Lyramid Limited ("Lyramid"). It is intended that Mr Freeman will retain his position as one of the two Australian resident directors required to be appointed to the Board of Lyramid after the proposed acquisition of Lyramid has completed.

 

Stephen West, Executive Chairman, commented:

"As we work towards completion of the Lyramid transaction, it is important to have a financially oritentated Australian resident director with public markets experience to assist the Company going forward. We are therefore delighted that Mark Freeman has agreed to join the Company as a non-executive director given his proven track record and experience in this regard. I would like to thank Glenn Whiddon for working with us from the formation of Roquefort Investments up to this transformational stage for the Company.

 

The Board is focused on completing the Lyramid transaction and the RTO process and we look forward to providing a further update on this shortly."

 

Enquiries:

 

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Joint Broker)

 

Christian Dennis

+44 (0) 20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFFEFIUEFSEIS
Date   Source Headline
30th Jun 20224:38 pmRNSDirector/PDMR Shareholding
30th Jun 202210:30 amRNSResult of AGM
23rd Jun 20227:00 amRNSUpdate on Acquisition of Oncogeni and Placing
22nd Jun 20224:42 pmRNSIssue of Warrants
22nd Jun 202210:32 amRNSInvestor Presentation
22nd Jun 20229:05 amRNSSecond Price Monitoring Extn
22nd Jun 20229:00 amRNSPrice Monitoring Extension
22nd Jun 20227:00 amRNSProposed Acquisition of Oncogeni Limited & Placing
13th Jun 20227:00 amRNSNotice of AGM - Correction
7th Jun 20227:00 amRNSNotice of AGM
7th Jun 20227:00 amRNSPre-clinical Update
11th May 20227:00 amRNSAnnual Report & Financial Statements
20th Apr 20227:00 amRNSNon-Executive Director Appointment
5th Apr 20227:00 amRNSBoard Appointment
22nd Mar 20228:08 amRNSHolding(s) in Company
21st Mar 20229:34 amRNSInvestor Presentation
21st Mar 20227:00 amRNSPatent Filed – New Drug Class Targeting Midkine
8th Mar 20227:54 amRNSHolding(s) in Company
14th Feb 20227:00 amRNSAppointment of Strategic & Scientific Advisor
8th Feb 202211:35 amRNSHolding(s) in Company
28th Jan 20227:00 amRNSHolding(s) in Company
19th Jan 202212:56 pmRNSDirector/PDMR Shareholding
19th Jan 20228:39 amRNSHolding(s) in Company
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:51 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSPre-clinical Update
10th Jan 20228:00 amRNSPublication of New Research
31st Dec 20217:00 amRNSChange of Company Name
22nd Dec 20217:00 amRNSHolding(s) in Company
21st Dec 20219:06 amRNSSecond Price Monitoring Extn
21st Dec 20219:00 amRNSPrice Monitoring Extension
21st Dec 20217:00 amRNSAcquisition Completion, Admission & Voting Rights
16th Dec 20214:24 pmRNSPublication of Prospectus
13th Dec 20211:19 pmRNSResults of General Meeting
22nd Nov 20217:00 amRNSConditional Placing to Raise £3 Million
19th Nov 20217:00 amRNSCircular and Notice of General Meeting
18th Nov 20217:00 amRNSProposed Acquisition of Lyramid Pty Limited
12th Nov 20217:33 amRNSUpdate on Acquisition of Lyramid Limited
29th Oct 20212:01 pmRNSInterim Results to 30 June 2021
20th Oct 20217:00 amRNSBoard Changes
29th Sep 20217:34 amRNSReverse Takeover & Suspension of Trading
29th Sep 20217:30 amRNSSuspension - Roquefort Investments Plc
26th Aug 202112:42 pmRNSHolding(s) in Company
25th Aug 202111:06 amRNSSecond Price Monitoring Extn
25th Aug 202111:00 amRNSPrice Monitoring Extension
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20212:44 pmRNSHolding(s) in Company
24th Aug 20212:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.